Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy? / A. Di Biagio, R. Prinapori, L. Taramasso, G. Gustinetti, L. Sticchi, B. Bruzzone, C. Viscoli. - In: RECENT PATENTS ON ANTI-INFECTIVE DRUG DISCOVERY. - ISSN 1574-891X. - 9:1(2014 Jan), pp. 41-51. [10.2174/1574891X09666140717102358]
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
L. Taramasso;
2014
Abstract
Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Di Biagio, Recent Pat Antiinfect Drug Discov. 2014.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
7.32 MB
Formato
Adobe PDF
|
7.32 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
